Diadexus, Inc. Share Price

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

OTC Markets Traded
Delayed 5-day change 1st Jan Change
- USD -.--% Intraday chart for Diadexus, Inc. -.--% -

Valuation: Diadexus, Inc.

Market Cap 49.2T 44.14T 40.81T 36.96T 69.05T 46.86L 69.89T 5L 2L 24.52L 2L 2L 77.84L P/E 2014
-3.26x
P/E 2015 -1.14x
Enterprise Value 52.9L 47.46L 43.88L 39.74L 74.25L 50Cr 75.15L 5.25Cr 2.09Cr 26Cr 1.99Cr 1.94Cr 84Cr EV / Sales 2014
1.05x
EV / Sales 2015 0.77x
Free-Float
100%
Yield 2014 *
-
Yield 2015 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 410
+1.03%+1.86%+57.83%+128.81% 1,14300Cr
+0.97%+5.24%+45.13%+84.52% 65TCr
+0.14%+0.61%+25.93%+101.95% 51TCr
-0.05%+1.73%+52.74%+65.27% 38TCr
-0.74%-6.39%+61.22%+36.65% 35TCr
+0.34%+1.84%+30.70%+52.69% 29TCr
-0.45%+1.19%+2.89%+24.92% 26TCr
+0.62%+2.55%+53.90%+70.80% 24TCr
0.00%+3.34%+34.63%+104.06% 20TCr
Average +0.16%+0.76%+40.55%+74.41% 40.28TCr
Weighted average by Cap. +0.40%+0.71%+44.63%+87.17%

Financials

2014 2015
Net sales 2.61Cr 2.34Cr 2.17Cr 1.96Cr 3.66Cr 248.69Cr 3.71Cr 26Cr 10Cr 130.14Cr 9.8Cr 9.59Cr 413.13Cr 1.79Cr 1.6Cr 1.48Cr 1.34Cr 2.51Cr 170.33Cr 2.54Cr 18Cr 7.06Cr 89Cr 6.71Cr 6.57Cr 282.95Cr
Net income -84.67L -75.97L -70.23L -63.61L -1.19Cr -81Cr -1.2Cr -8.4Cr -3.34Cr -42Cr -3.18Cr -3.11Cr -133.96Cr -71.66L -64.29L -59.44L -53.83L -1.01Cr -68Cr -1.02Cr -7.11Cr -2.83Cr -36Cr -2.69Cr -2.63Cr -113.38Cr
Net Debt -2L -2L -2L -1L -3L -1.89Cr -3L -19.64L -8L -98.68L -7L -7L -3.13Cr 52.41L 47.02L 43.47L 39.37L 73.56L 50Cr 74.45L 5.2Cr 2.07Cr 26Cr 1.97Cr 1.93Cr 83Cr
Logo Diadexus, Inc.
Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
Employees
-
  1. Stock Market
  2. Stocks
  3. DDXSQ Stock